Quantinno Capital Management LP Has $11.98 Million Stock Holdings in Boston Scientific Co. (NYSE:BSX)

Quantinno Capital Management LP grew its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 47.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 134,139 shares of the medical equipment provider's stock after buying an additional 43,050 shares during the period. Quantinno Capital Management LP's holdings in Boston Scientific were worth $11,981,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Pathstone Holdings LLC grew its holdings in shares of Boston Scientific by 1.3% during the fourth quarter. Pathstone Holdings LLC now owns 126,091 shares of the medical equipment provider's stock valued at $11,263,000 after purchasing an additional 1,659 shares during the last quarter. Mufg Securities Americas Inc. bought a new position in shares of Boston Scientific during the fourth quarter valued at approximately $1,943,000. Man Group plc grew its holdings in Boston Scientific by 30.1% in the 4th quarter. Man Group plc now owns 271,059 shares of the medical equipment provider's stock worth $24,211,000 after buying an additional 62,662 shares in the last quarter. NorthRock Partners LLC grew its holdings in Boston Scientific by 161.5% in the 4th quarter. NorthRock Partners LLC now owns 15,876 shares of the medical equipment provider's stock worth $1,418,000 after buying an additional 9,805 shares in the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Boston Scientific by 22.1% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 8,334 shares of the medical equipment provider's stock worth $744,000 after buying an additional 1,507 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Insider Activity

In other news, EVP Arthur C. Butcher sold 17,314 shares of the firm's stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $102.06, for a total value of $1,767,066.84. Following the sale, the executive vice president now directly owns 22,235 shares of the company's stock, valued at approximately $2,269,304.10. This trade represents a 43.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Daniel J. Brennan sold 67,333 shares of the firm's stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total value of $7,086,124.92. Following the completion of the sale, the chief financial officer now directly owns 225,808 shares in the company, valued at approximately $23,764,033.92. This represents a 22.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 265,820 shares of company stock valued at $27,406,958. 0.50% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on BSX shares. Royal Bank of Canada increased their price target on Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a research note on Thursday, April 24th. Erste Group Bank upgraded Boston Scientific to a "strong-buy" rating in a research report on Thursday, May 8th. StockNews.com upgraded Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Evercore ISI increased their target price on Boston Scientific from $110.00 to $112.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Finally, Raymond James increased their target price on Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a report on Thursday, February 6th. Twenty-three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $114.74.

Boston Scientific Stock Up 1.1%

Boston Scientific stock traded up $1.14 during mid-day trading on Friday, hitting $106.00. 7,288,742 shares of the company's stock were exchanged, compared to its average volume of 6,362,890. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The stock has a market cap of $156.83 billion, a P/E ratio of 84.80, a P/E/G ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a 1-year low of $71.88 and a 1-year high of $107.17. The stock has a 50 day moving average of $99.18 and a two-hundred day moving average of $96.66.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.67 by $0.08. The firm had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The business's quarterly revenue was up 20.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.56 earnings per share. As a group, analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.